Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination medication consisting of bupivacaine, an amide local anesthetic, and hydromorphone, an opioid analgesic. This combination is primarily used in intrathecal (IT) drug delivery systems for managing chronic pain, particularly in patients with failed back surgery syndrome (FBSS) or post-laminectomy syndrome. The combination has shown effectiveness in reducing pain intensity and oral opioid consumption, with bupivacaine helping to attenuate the opioid dose escalation phenomenon commonly observed with intrathecal opioid monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + hydromorphone.